Skip to main content

Nosocomial Pneumonia News

FDA Approves Merck’s Recarbrio (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)

KENILWORTH, N.J.--(BUSINESS WIRE) June 5, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved a...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related drug support groups

Cipro, ciprofloxacin, Levaquin, levofloxacin, vancomycin